Eagle Bay Advisors’s Edwards Lifesciences EW Stock Holding History

Eagle Bay Advisors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,640	Closed	-$225K	–	174
2025 Q4	$225K	Hold	2,640	–	–	0.16%	102
2025 Q3	$205K	Sell	2,640 -51	-2%	-$3.98K	0.16%	104
2025 Q2	$210K	Buy	+2,691	New	+$201K	0.17%	103
2025 Q1	–	Sell	-2,691	Closed	-$199K	–	397
2024 Q4	$199K	Sell	2,691 -49	-2%	-$3.43K	0.13%	113
2024 Q3	$181K	Sell	2,740 -550	-17%	-$40K	0.07%	186
2024 Q2	$304K	Hold	3,290	–	–	0.18%	83
2024 Q1	$314K	Buy	3,290 +49	+2%	+$4.12K	0.2%	84
2023 Q4	$247K	Sell	3,241 -200	-6%	-$13.9K	0.16%	112
2023 Q3	$238K	Buy	3,441 +2,640	+330%	+$212K	0.11%	123
2023 Q2	$75.6K	Hold	801	–	–	0.04%	283
2023 Q1	$66.3K	Hold	801	–	–	0.04%	323
2022 Q4	$59.8K	Hold	801	–	–	0.03%	337
2022 Q3	$66K	Hold	801	–	–	0.04%	286
2022 Q2	$76.2K	Buy	+801	New	+$82.9K	0.05%	264
2022 Q1	–	Sell	-782	Closed	-$102K	–	516
2021 Q4	$102K	Sell	782 -46	-6%	-$5.37K	0.07%	180
2021 Q3	$93K	Buy	+828	New	+$94.5K	0.05%	262

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Eagle Bay Advisors's EW Position: Q1 2026 in Review

Eagle Bay Advisors sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 2,640 shares — an estimated $225K sold.

Eagle Bay Advisors first reported a position in EW in Q3 2021 and held it in 16 quarters. The position peaked at $314K in Q1 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Eagle Bay Advisors reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
Eagle Bay Advisors sold 2,640 Edwards Lifesciences shares in Q1 2026, an estimated $225K.
Eagle Bay Advisors first reported a position in Edwards Lifesciences in Q3 2021 and held it in 16 quarters.
Eagle Bay Advisors's Edwards Lifesciences position peaked at $314K in Q1 2024.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Eagle Bay Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.